Biocartis Group NV is a prominent company known for its strong values and corporate philosophy. With a focus on innovation and advanced technologies, Biocartis Group NV is passionate about improving personalized medicine. The company firmly believes in building partnerships and collaborations to enhance the efficiency and effectiveness of healthcare delivery. By integrating molecular diagnostics, Biocartis Group NV aims to revolutionize diagnostics and enable better patient outcomes. Through their continuous commitment to excellence, Biocartis Group NV strives to be a leader in precision medicine, offering reliable and accurate testing solutions.

Biocartis Group NV is primarily present in various countries and regions worldwide. The company has a strong presence in Europe, particularly in Belgium, where it is headquartered. Biocartis also has a significant presence in the United States, as it operates a subsidiary in New Jersey. Additionally, the company has expanded its reach to other regions, including Asia, Africa, and the Middle East. By establishing strategic partnerships and collaborations, Biocartis aims to serve the global healthcare market with its innovative molecular diagnostics solutions.

Biocartis Group NV, a leading molecular diagnostics company, has achieved several significant milestones. It successfully launched its flagship molecular diagnostics platform, Idylla™, which enables fast and accurate diagnostic testing for a wide range of diseases. The company has also established partnerships with renowned institutions and organizations, strengthening its global presence and market reach. Biocartis Group NV has consistently demonstrated its commitment to innovation, regularly introducing new assays and expanding the applications of its technology. Moreover, the company has obtained various regulatory clearances and certifications, reaffirming its dedication to providing reliable and high-quality diagnostic solutions. Biocartis Group NV's relentless pursuit of advancements in molecular diagnostics has positioned it as a key player in the industry.

Biocartis Group NV is a leading molecular diagnostics company, headquartered in Mechelen, Belgium. Founded in 2007, Biocartis focuses on providing innovative diagnostic solutions to improve patient outcomes in the field of oncology. The company developed the Idylla™ platform, a fully automated molecular diagnostics system, which enables fast and accurate testing of various biomarkers. Biocartis has successfully partnered with renowned pharmaceutical companies and diagnostic laboratories worldwide to deliver personalized medicine solutions. With its strong commitment to research and development, Biocartis continues to revolutionize the molecular diagnostics industry, contributing to advancements in precision medicine and patient care.

The main competitors of Biocartis Group NV in the market include companies such as Illumina, Thermo Fisher Scientific, and QIAGEN.

Biocartis Group NV is primarily active in the healthcare and life sciences industries.

The business model of Biocartis Group NV focuses on the development and commercialization of innovative diagnostics solutions. Biocartis specializes in molecular diagnostics, offering a wide range of reliable and easy-to-use molecular diagnostic platforms that enable fast and accurate testing for various diseases and conditions. By combining advanced technology and extensive research expertise, Biocartis aims to provide healthcare professionals with efficient tools for personalized medicine, leading to better patient outcomes. With a customer-centric approach and diverse product portfolio, Biocartis strives to address unmet medical needs and improve the diagnostics landscape.

Poměr Biocartis Group P/E je -0,19.

Koeficient Biocartis Group tržních hodnot je 0,22.

AlleAktien kvalitní skóre pro Biocartis Group je 5/10.

očekávané Biocartis Group obrat je 78,28 mil. EUR.

očekávané Biocartis Group zisk je -91,18 mil. EUR.

The Biocartis Group NV is a Belgium-based medical technology company that offers innovative diagnostic solutions for the field of molecular diagnostics. It aims to simplify, accelerate, and personalize the diagnosis of cancer and infectious diseases through the use of technology. Biocartis combines proprietary platforms with collaborations with leading pharmaceutical and diagnostic companies. Biocartis' core business is the development and marketing of its molecular diagnostic platforms, which are based on the proprietary technology of the original Idylla™ platform. This platform allows for the identification of disease-relevant biomarkers in tissue or blood samples of patients and their diagnosis within 15 to 150 minutes through a rapid test. Biocartis offers the following Idylla™ platforms: - Idylla™ Console: A fully automated diagnostic system for the rapid and precise analysis of biomarkers in tissue samples. - Idylla™ cartridges: A range of test cartridges specifically designed for use with the Idylla™ platform, typically detecting biomarkers for cancer and infectious diseases. - Idylla™ global network: A workspace connecting test centers and laboratories worldwide, allowing for real-time exchange of patient data and test results. The Idylla™ platforms aim to compete with traditional histopathological diagnostics, which can be time-consuming and prone to misinterpretation. They offer faster and more accurate diagnostics, enabling physicians and clinics to treat more quickly and effectively. In addition to its Idylla™ platforms, Biocartis also offers a range of research products including: - MyCartis™: A platform for protein analysis that allows researchers to quantitatively measure proteins in a very short time. - AMR Rapid Test: A rapid test for diagnosing antimicrobial resistances, determining the sensitivity of bacteria to antibiotics. - Liquid biopsy tests: Tests for detecting cancer in blood by detecting circulating tumor cells or tumor DNA. An important pillar of Biocartis' business model is its collaboration with pharmaceutical and diagnostic companies to develop new tests for the Idylla™ platform. The company has partnerships and collaborations with leading companies in the industry, including Amgen, Merck, Bristol-Myers Squibb, Qiagen, and Nestlé Health Science. This collaboration allows Biocartis to develop new biomarkers and test cartridges for its platforms, expanding the offering for physicians and patients. In summary, the Biocartis Group NV offers innovative molecular diagnostic platforms based on proprietary technology, enabling faster and more accurate diagnosis of cancer and infectious diseases. The company leverages its expertise and collaboration with leading companies in the industry to develop new tests for its platforms and expand the offering for physicians and patients. Please, let me know if I can help you with anything else.

Biocartis Group vyplácí dividendu ve výši 0 EUR rozdělenou do výplat během roku.

Dividenda pro Biocartis Group momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Biocartis Group je BE0974281132.

WKN společnosti Biocartis Group je A14R82.

Ticker společnosti Biocartis Group je BCART.BR.

Během posledních 12 měsíců vyplatila společnost Biocartis Group dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Biocartis Group vyplatí dividendu ve výši 0 EUR.

Výnos z dividend společnosti Biocartis Group aktuálně činí .

Biocartis Group vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Biocartis Group vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 EUR. To odpovídá dividendovému výnosu 0 %.

Biocartis Group je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Biocartis Group ve výši 0 EUR, zaznamenané 24. 11. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 24. 11. 2024.

Poslední dividendy byly vyplaceny dne 24. 11. 2024.

V roce 2023 společností Biocartis Group bylo vyplaceno 0 EUR ve formě dividend.

Dividendy společnosti Biocartis Group jsou vypláceny v EUR.